In this interview, Adam Hill, CEO of Oncimmune #ONC - a global immunodiagnostics firm with a leading position in autoimmune profiling - explains:
How the ImmunoINSIGHTS platform is typically used. Start
Strategy of developing preferred supplier agreements with the world’s top BioPharmas. 03:35
The division's H1 performance & expected growth trajectory for the rest of the year. 06:15
Possible M&A opportunities. 12:20
Does the group need to consider strengthening its balance sheet? 13:45
Update on the EarlyCDT lung cancer test. 14:40
Why is the yearend being changed from May to Aug? 16:50
Future newsflow. 18:25
Typical contract values/duration. 19:20
Size of orderbook 20:25
Q&A with Oncimmune CEO, Dr Adam M Hill
Feb 28, 2022Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.